All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View lymphoma & CLL content recommended for you
Visual abstract | BOVen in patients with TN CLL/SLL: Long-term follow-up results
Do you know... What is the goal of using MRD to guide treatment with the BOVen regimen?
A multicenter, phase II trial (NCT03824483) is evaluating the efficacy and safety of zanubrutinib + obinutuzumab + venetoclax (BOVen) in patients with treatment-naïve (TN) chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) or mantle cell lymphoma (MCL).1
The Lymphoma Hub previously reported results from an analysis of the BOVen regimen in older patients with TN MCL (N = 50) using a measurable residual disease (MRD)-driven time-limited approach.2 The best overall response rate was 98%, with a complete metabolic response rate of 96%.2 After a median follow-up of 25 months, the 2-year progression-free survival rate and overall survival rates were 86% and 92%, respectively.2 The safety profile was manageable, with expected toxicities.2
Here, we present a visual abstract outlining/summarizing long-term follow-up results from an analysis of the BOVen regimen in patients with TN CLL/SLL (median age, 62 years) published in Blood Advances by Soumerai et al.3 This study aimed to optimize treatment duration using MRD-guided treatment/retreatment to balance efficacy against toxicities associated with extended treatment exposure.3
Visual abstract | BOVen in patients with TN CLL/SLL: Long-term follow-up results
This educational resource is independently supported by BeOne Medicines USA. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
Your opinion matters
When selecting the next therapy for patients with R/R MCL after BTKi progression, what is your most important consideration?
.jpeg)
